Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Eli Lilly to offer early access to next-gen obesity drug to some patients

4 August 2026 · By · Wire by Fusion42

Published

4 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at reuters.com →

◆ Verified

Fusion42 · 1 September 2026 · Fusion42 review

Eli Lilly announced an expanded access program to provide limited early access to its experimental next-generation obesity drug, retatrutide, to eligible patients in the U.S. before FDA approval.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 4 Aug 2026 and 7 Aug 2026.

◆ ◆ The Wire takeaway

You gain an early route to serve patients excluded from clinical trials through Lilly’s access program, creating an opportunity to build clinical evidence and trust ahead of formal approval.

◆ Coverage

2 sources · first reported 4 Aug 2026 · latest 7 Aug 2026

◆ Related on Wire

◆ Topics

Biotechobesity-drugexpanded-accessFDAclinical-trialsretatrutide